MedTrace Logo

Effect of CBD-Based Vaginal Suppositories on Menopausal Symptoms

NCT06804889 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-02-03

No results posted yet for this study

Summary

Efficacy and safety of the medical device CANNEFF® vaginal suppositories containing two active ingredients cannabidiol (CBD) and hyaluronic acid (HA) in alleviating menopausal symptoms and improving quality of life in (post)menopausal women will be evaluated.

Conditions

  • Menopause and Genitourinary Syndrome

Interventions

DEVICE

CANNEFF® VAG SUP vaginal suppositories

CANNEFF® VAG SUP vaginal suppositories containing 100 mg cannabidiol - CBD and 6.6 mg hyaluronic acid - HA.

DEVICE

Placebo Suppositories

Received placebo vaginal suppositories with identical composition as for Active Comparator, but without both active ingredients (CBD - cannabidiol and HA - hyaluronic acid).

Sponsors & Collaborators

  • CB21 Pharma Ltd.

    collaborator UNKNOWN

  • Palacky University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-01-01
Completion
2024-02-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06804889 on ClinicalTrials.gov